Related Articles by Review for PMID: 15231010

Year	Number of Results
1990	1
1991	1
1992	3
1993	1
1994	1
1995	3
1996	3
1997	2
1998	4
1999	2
2000	3
2001	8
2002	6
2003	12
2004	16
2005	12
2006	26
2007	18
2008	19
2009	9
2010	4
2011	8
2012	1
2013	5
2014	6
2015	6
2016	12
2017	4
2018	3
2019	4
2020	1
2021	3
2022	2
2023	2
2024	1

1

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

Chesnut CH 3rd, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD; Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE). Chesnut CH 3rd, et al. J Bone Miner Res. 2004 Aug;19(8):1241-9. doi: 10.1359/JBMR.040325. Epub 2004 Mar 29. J Bone Miner Res. 2004. PMID: 15231010 Free article. Clinical Trial.

2

Beyond daily dosing: clinical experience.

Cooper C. Cooper C. Bone. 2006 Apr;38(4 Suppl 1):S13-7. doi: 10.1016/j.bone.2006.01.152. Epub 2006 Mar 7. Bone. 2006. PMID: 16520105 Review.

3

Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg.

Epstein S, Jeglitsch M, McCloskey E. Epstein S, et al. Curr Med Res Opin. 2009 Dec;25(12):2951-60. doi: 10.1185/03007990903361307. Curr Med Res Opin. 2009. PMID: 19835464 Review.

4

Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy.

Miller PD. Miller PD. Clin Ther. 2005 Apr;27(4):361-76. doi: 10.1016/j.clinthera.2005.04.005. Clin Ther. 2005. PMID: 15922811 Review.

5

Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review.

Rossini M, Viapiana O, Gatti D, Adami S. Rossini M, et al. Clin Ther. 2009 Jul;31(7):1497-510. doi: 10.1016/j.clinthera.2009.07.018. Clin Ther. 2009. PMID: 19695399 Review.

6

Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen.

Pyon EY. Pyon EY. Clin Ther. 2006 Apr;28(4):475-90. doi: 10.1016/j.clinthera.2006.04.006. Clin Ther. 2006. PMID: 16750461 Review.

7

Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review.

Reginster JY. Reginster JY. Curr Pharm Des. 2005;11(28):3711-28. doi: 10.2174/138161205774580750. Curr Pharm Des. 2005. PMID: 16305506 Review.

8

Once-monthly dosing: an effective step forward.

Reid DM. Reid DM. Bone. 2006 Apr;38(4 Suppl 1):S18-22. doi: 10.1016/j.bone.2006.01.153. Epub 2006 Mar 13. Bone. 2006. PMID: 16533625 Review.

9

A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate.

Reginster JY, Felsenberg D, Cooper C, Stakkestad JA, Miller PD, Kendler DL, Adami S, McClung MR, Bolognese MA, Civitelli R, Dumont E, Bonvoisin B, Recker RR, Delmas PD. Reginster JY, et al. Osteoporos Int. 2006 Feb;17(2):159-66. doi: 10.1007/s00198-005-1957-6. Epub 2005 Jun 14. Osteoporos Int. 2006. PMID: 15959614 Review.

10

Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies.

Schimmer RC, Bauss F. Schimmer RC, et al. Clin Ther. 2003 Jan;25(1):19-34. doi: 10.1016/s0149-2918(03)90005-1. Clin Ther. 2003. PMID: 12637110 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

201 results

Results by year